​

Funding Round

Series A - Anokion

Series A - Anokion

Investment Firm

Overview

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Announced Date

May 09, 2014

Funding Type

Series A

Highlights

Location

Switzerland, Europe

Social

Investor Lead

Versant Ventures

Versant Ventures

Versant Ventures is a early_stage_venture and late_stage_venture and post_ipo firm.

Novartis Venture Fund

Novartis Venture Fund

Novartis Venture Fund is a early_stage_venture and late_stage_venture and post_ipo and seed firm.

Novo Ventures

Novo Ventures

Novo Ventures is a early_stage_venture and late_stage_venture firm.

Participant Investors

5

Investor Name
Participant InvestorHarry Welten
Participant InvestorNovo Ventures
Participant InvestorAndré J. Mueller
Participant InvestorNovartis Venture Fund
Participant InvestorVersant Ventures

Round Details and Background

Anokion raised $37500000 on 2014-05-09 in Series A

Anokion is harnessing the power of natural immune equilibrium to develop solutions for antigen-specific immune tolerance.

Company Funding History

4

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Dec 12, 2011
Debt Financing - Anokion
1-106.9K
Sep 11, 2019
Series B - Anokion
4-40.0M
Oct 18, 2022
Venture Round - Anokion
1-35.0M
May 09, 2014
Series A - Anokion
5-37.5M

Recent Activity

There is no recent news or activity for this profile.